GlassScriptPhysician profile
David Y Shek
NPI 1346289915
$54,433.63
in general payments reported to CMS, 2019-2025
64 companies · $7,007 in 2025
The $7,007 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,287 · 2021: $7,843 · 2022: $7,654 · 2023: $8,014 · 2024: $8,792 · 2025: $7,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23,813.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,112.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $7,047.77 | 2019-2025 | Repatha, Evenity, Otezla |
| Gilead Sciences, INC. | $6,106.15 | 2019-2025 | Vemlidy, Epclusa, Livdelzi |
| Glaxosmithkline, LLC. | $3,447.30 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $3,135.98 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $3,020.72 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,281.75 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $2,207.99 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Novo Nordisk INC | $1,603.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,474.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,414.86 | 2021-2025 | |
| Amarin Pharma, INC. | $1,336.22 | 2019-2023 | |
| Allergan, INC. | $1,227.00 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $656.20 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Cequr Corporation | $595.57 | 2022-2025 | Cequr Simplicity |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.